|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
|
EP3434275A1
(en)
|
2003-11-06 |
2019-01-30 |
Seattle Genetics, Inc. |
Assay for cancer cells based on the use of auristatin conjugates with antibodies
|
|
EA020324B1
(ru)
*
|
2006-07-18 |
2014-10-30 |
Санофи-Авентис |
АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
|
|
CA2691075C
(en)
|
2007-06-15 |
2017-04-11 |
Daniela Gast |
Treatment of tumors using specific anti-l1 antibody
|
|
ATE543835T1
(de)
|
2007-07-16 |
2012-02-15 |
Genentech Inc |
Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
|
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
|
SI2199390T1
(sl)
|
2007-08-30 |
2017-02-28 |
Daiichi Sankyo Company, Limited |
Proti-epha2 protitelo
|
|
EP2235055A2
(en)
*
|
2007-12-24 |
2010-10-06 |
Oxford Biotherapeutics Ltd. |
Ephrin type-a receptor 10 protein
|
|
PT2247620T
(pt)
|
2008-01-31 |
2016-08-23 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
|
US20100009390A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Mutant antibodies with high affinity for egfr
|
|
US20100008978A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Nanoparticles effective for internalization into cells
|
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
|
TWI504410B
(zh)
|
2010-02-08 |
2015-10-21 |
Agensys Inc |
結合至１６１ｐ２ｆ１０ｂ蛋白之抗體藥物結合物（ａｄｃ）
|
|
US9128101B2
(en)
|
2010-03-01 |
2015-09-08 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
WO2011127219A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings |
Circulating biomarkers for disease
|
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
|
ES2961381T3
(es)
|
2010-06-19 |
2024-03-11 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-GD2
|
|
WO2012012759A2
(en)
*
|
2010-07-22 |
2012-01-26 |
The Regents Of The University Of California |
Anti-tumor antigen antibodies and methods of use
|
|
SG187908A1
(en)
|
2010-08-20 |
2013-03-28 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
EP3786185A1
(en)
|
2010-12-06 |
2021-03-03 |
Seagen Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
TWI655210B
(zh)
|
2010-12-08 |
2019-04-01 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎調節劑及其使用方法
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
EP3501546A3
(de)
*
|
2011-04-21 |
2019-09-18 |
Seattle Genetics, Inc. |
Cystein-wirkstoff konjugate und ihre verwendung
|
|
US20120308584A1
(en)
*
|
2011-05-08 |
2012-12-06 |
Legochem Biosciences, Inc. |
Protein-active agent conjugates and method for preparing the same
|
|
MX350957B
(es)
*
|
2011-11-23 |
2017-09-27 |
Medimmune Llc |
Moleculas de union especificas para her3 y usos de las mismas.
|
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
JP2015500829A
(ja)
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
|
|
SG11201407017WA
(en)
|
2012-06-04 |
2014-12-30 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
WO2014011987A1
(en)
*
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating car t cells
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
ES2738310T3
(es)
|
2012-10-12 |
2020-01-21 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
CA2900755C
(en)
|
2013-02-08 |
2021-07-20 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
MX375354B
(es)
*
|
2013-03-13 |
2025-03-06 |
Prothena Biosciences Ltd |
Anticuerpos que se unen a tau y usos de los mismos.
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Ｎｏｔｃｈ３に対する抗体
|
|
US10167341B2
(en)
|
2013-03-15 |
2019-01-01 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
|
BR112015021134A2
(pt)
|
2013-03-15 |
2017-10-10 |
Novartis Ag |
conjugados de fármaco e anticorpo
|
|
WO2015048008A2
(en)
|
2013-09-24 |
2015-04-02 |
Medimmune, Llc |
Binding molecules specific for her3 and uses thereof
|
|
BR112016010051A2
(pt)
*
|
2013-11-04 |
2017-12-05 |
Pfizer |
?conjugados de anticorpo-fármaco anti-efna4?
|
|
EP3092255A4
(en)
|
2014-01-10 |
2017-09-20 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating egfr expressing tumors
|
|
CN106659800A
(zh)
|
2014-03-12 |
2017-05-10 |
诺华股份有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
EP3137114B8
(en)
|
2014-04-30 |
2021-08-04 |
Pfizer Inc. |
Anti-ptk7 antibody-drug conjugates
|
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
AU2015287749B2
(en)
*
|
2014-07-11 |
2021-03-11 |
The Regents Of The University Of California |
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
PE20170903A1
(es)
|
2014-08-12 |
2017-07-12 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
AU2015327064B2
(en)
|
2014-09-30 |
2021-03-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Binding molecules, especially antibodies, binding to L1CAM (CD171)
|
|
WO2016055907A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Pfizer Inc. |
Synergistic auristatin combinations
|
|
KR102754019B1
(ko)
|
2014-10-29 |
2025-01-14 |
바이시클러드 리미티드 |
Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
EP3405492B1
(en)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
AU2017235545A1
(en)
*
|
2016-03-15 |
2018-10-25 |
Seagen Inc. |
Combination therapy using a LIV1-ADC and a chemotherapeutic
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
WO2018069289A1
(en)
|
2016-10-11 |
2018-04-19 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
IL326918A
(en)
|
2016-10-19 |
2026-05-01 |
Invenra Inc |
Antibody structures
|
|
JP7681879B2
(ja)
|
2016-12-22 |
2025-05-23 |
ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ |
Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
KR20200019226A
(ko)
|
2017-06-23 |
2020-02-21 |
버디 바이오파마슈티칼즈, 인크. |
약학 조성물
|
|
CN111032678A
(zh)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
具有可检测部分的双环肽配体和其用途
|
|
WO2019016772A2
(en)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR TREATING CANCER
|
|
ES2926195T3
(es)
|
2017-08-04 |
2022-10-24 |
Bicycletx Ltd |
Ligandos peptídicos bicíclicos específicos de CD137
|
|
EP3694545A4
(en)
*
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
US20200347130A1
(en)
*
|
2017-11-10 |
2020-11-05 |
Jiangsu Hengrui Medicine Co., Ltd. |
CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
|
|
AU2019224659A1
(en)
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
CA3092695A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Human pd-l2 antibodies and methods of use therefor
|
|
WO2019182867A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
|
US12187799B2
(en)
|
2018-03-23 |
2025-01-07 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
|
|
SG11202010469QA
(en)
|
2018-05-23 |
2020-11-27 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12172986B2
(en)
|
2018-06-01 |
2024-12-24 |
Eisai R&D Management Co., Ltd |
Splicing modulator antibody-drug conjugates and methods of use
|
|
CA3102349A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
|
EP3801635A4
(en)
*
|
2018-06-07 |
2022-04-06 |
Magenta Therapeutics, Inc. |
THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATES (ADCS)
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810316D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
WO2020076849A1
(en)
|
2018-10-11 |
2020-04-16 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
PE20211473A1
(es)
|
2018-12-13 |
2021-08-05 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
CN113474045A
(zh)
|
2018-12-21 |
2021-10-01 |
拜斯科技术开发有限公司 |
Pd-l1特异性的双环肽配体
|
|
PH12021551479A1
(en)
|
2018-12-21 |
2022-07-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CA3189761A1
(en)
|
2020-08-03 |
2022-02-10 |
Gemma Mudd |
Peptide-based linkers
|
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CR20230283A
(es)
|
2020-11-24 |
2023-07-27 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
US12162945B2
(en)
|
2021-03-05 |
2024-12-10 |
Immunome, Inc. |
EPHA2 antibodies
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
CA3236173A1
(en)
|
2021-10-22 |
2023-04-27 |
Centenaire Biosciences, Inc. |
Antigen-binding protein comprising two fc domains and use thereof
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
WO2023157989A1
(ko)
|
2022-02-17 |
2023-08-24 |
주식회사 노벨티노빌리티 |
항체-약물 접합체
|
|
JP2025517430A
(ja)
|
2022-05-20 |
2025-06-05 |
ノバルティス アーゲー |
Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
|
|
PE20251072A1
(es)
|
2022-05-20 |
2025-04-10 |
Novartis Ag |
Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
|
|
CN120752058A
(zh)
|
2023-03-10 |
2025-10-03 |
诺华股份有限公司 |
panRAS抑制剂抗体-药物缀合物及其使用方法
|
|
WO2024219894A1
(ko)
|
2023-04-21 |
2024-10-24 |
상트네어바이오사이언스 주식회사 |
두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
|
|
WO2026069006A1
(en)
|
2024-09-30 |
2026-04-02 |
Sunrise Oncology (Hong Kong) Limited |
Ras inhibitor antibody-drug conjugates and methods of use thereof
|